1,124
Participants
Start Date
September 29, 2021
Primary Completion Date
August 12, 2022
Study Completion Date
August 12, 2022
Ad26.RSV.preF-based Vaccine
Participants will receive a single IM injection of an RSV vaccine.
Placebo
Participants will receive a single IM injection of matching placebo.
Anima, Alken
Private Practice RESPISOM Namur, Namur
Emovis GmbH, Berlin
Klinische Forschung Berlin GbR, Berlin
Studieenheten Akademiskt Specialistcentrum Stockholm, Stockholm
Hosp Reina Sofia, Córdoba
Klinische Forschung Schwerin GmbH, Schwerin
Meridian Clinical Research, LLC, Rockville
Clinical Research HamburggmbH, Hamburg
ProbarE i Lund AB, Lund
Hosp Virgen de La Victoria, Málaga
Alliance for Multispeciality Research, Coral Gables
Research Institute of South Florida Inc, Miami
Alliance for Multispeciality Research, Knoxville
Zentrum fuer klinische Forschung, Cologne
Heartland Research Associates, an AMR Company, El Dorado
AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company, New Orleans
Tekton Research Inc., Yukon
C.H.U. St Pierre / Maladies Infectieuses, Brussels
Klinische Forschung Dresden GmbH, Dresden
SIBAmed GmbH & Co. KG, Leipzig
ClinSmart Sweden AB, Solna
ProbarE i Stockholm AB, Stockholm
Janssen Vaccines & Prevention B.V.
INDUSTRY